Chargement en cours...
Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges
Neoadjuvant immunotherapy involves administering immune checkpoint inhibitors before surgical resection in high-risk resectable disease. This strategy was shown to have a high pathological response rate and prolonged relapse-free survival in randomized trials in melanoma, glioblastoma, and colon can...
Enregistré dans:
| Publié dans: | J Natl Cancer Inst |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8246900/ https://ncbi.nlm.nih.gov/pubmed/33432320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djaa216 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|